Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718483 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01718483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01718483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
November 26, 2012
Completion date
September 25, 2013
Enrollment
383 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

binge eating disorder